Drug · CHEMBL741
LAMOTRIGINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. LAMOTRIGINE. Drugs and targets, record CHEMBL741. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL741
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 8 of its 36 diseases, from ATC, DailyMed, PMDA and TTD
- Open Targets
Targets10
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| SCN10A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6336 |
| SCN11A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/11280 |
| SCN1A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6323 |
| SCN2A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6326 |
| SCN3A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6328 |
| SCN4A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6329 |
| SCN5A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6331 |
| SCN7A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6332 |
| SCN8A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6334 |
| SCN9A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6335 |
Source ChEMBL
Diseases36
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 36Source Open Targets
See all 36 diseasesTrials187
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00277212 | A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode | Phase 4 | 1,169 | 2010-10-20 | lamotrigine | Its name | ClinicalTrials.gov |
| NCT00280059 | Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy | Phase 3 | 660 | 2011-10-24 | lamotrigine | Its name | ClinicalTrials.gov |
| NCT00088452 | Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study | Phase 3 | 453 | 2020-10-14 | lamotrigine | Its name | ClinicalTrials.gov |
| NCT00438451 | Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs | Phase 4 | 361 | 2013-02-28 | lamotrigine | Its name | ClinicalTrials.gov |
| NCT01674010 | Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder | Phase 2 | 309 | 2015-10-12 | lamotrigine | Its name | ClinicalTrials.gov |
| NCT00723450 | Lamictal as Add-on Treatment for Bipolar I Disorder in Pediatric Patients | Phase 3 | 301 | 2014-06-04 | lamotrigine | Its name | ClinicalTrials.gov |
| NCT00483548 | Adjunctive Ziprasidone in the Treatment of Bipolar I Depression | Phase 3 | 298 | 2010-02-23 | lamotrigine | Its name | ClinicalTrials.gov |
| NCT00531518 | Early Detection and Intervention for the Prevention of Psychosis | 292 | 2016-08-15 | lamotrigine | Its name | ClinicalTrials.gov | |
| NCT01602510 | Lamotrigine Phase III Study in Bipolar I Disorder | Phase 3 | 265 | 2017-01-23 | lamotrigine | Its name | ClinicalTrials.gov |
| NCT00355082 | Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy | Phase 3 | 226 | 2009-11-25 | lamotrigine | Its name | ClinicalTrials.gov |
1 to 10 of 187
See all 187 trialsComparisons in its trials66
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pregabalin vs Lamotrigine: Exit Due to Adverse Events During the Double-blind Treatment Phase (Including Dose Escalation Phase) | 33 of 330 | 31 of 330 | 660 | NCT00280059 | Trial comparisons |
| Pregabalin vs Lamotrigine: Exit for Any Reason During the Double-blind Treatment Phase (Including Dose Escalation Phase) | 94 of 330 | 80 of 330 | 660 | NCT00280059 | Trial comparisons |
| Pregabalin vs Lamotrigine: serious adverse events | 44 of 330 | 32 of 330 | 660 | NCT00280059 | Trial comparisons |
| Pregabalin vs Lamotrigine: Exit Due to Lack of Efficacy After 4-week Dose Escalation Phase | 78 of 329 | 58 of 330 | 659 | NCT00280059 | Trial comparisons |
| Pregabalin vs Lamotrigine: Exit Due to Any Reason After 4-week Dose Escalation Phase | 78 of 329 | 58 of 300 | 629 | NCT00280059 | Trial comparisons |
| Ziprasidone vs Placebo: serious adverse events | 1 of 147 | 6 of 147 | 294 | NCT00483548 | Trial comparisons |
| Family-aided Assertive Community Treatment vs Control Group: serious adverse events | 0 of 205 | 1 of 87 | 292 | NCT00531518 | Trial comparisons |
| Ziprasidone vs Placebo: MADRS Response: Number of Subjects With Total MADRS Score Reduction ≥ 50 Percent From Baseline at Week 6 | 62 of 145 | 65 of 145 | 290 | NCT00483548 | Trial comparisons |
| Ziprasidone vs Placebo: Clinical Global Impression - Improvement Scale (CGI-Improvement or CGI-I): Number of Subjects With Response (Much Improved or Very Much Improved) at Week 6 | 66 of 145 | 69 of 145 | 290 | NCT00483548 | Trial comparisons |
| Ziprasidone vs Placebo: MADRS Remission: Number of Subjects With Total MADRS Score ≤ 12 at Week 6 | 48 of 145 | 54 of 145 | 290 | NCT00483548 | Trial comparisons |
1 to 10 of 66
See all 66 comparisons in its trialsPapers from its trials111
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials17
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Verbal Learning | 5 | 2 | ConductCognition |
| Continuous Performance Test | 3 | 1 | ConductCognition |
| Verbal Fluency | 2 | 0 | ConductCognition |
| Complex Figure Copy and Recall | 1 | 0 | ConductCognition |
| Choice Reaction Time | 1 | 0 | ConductCognition |
| Design Fluency Test | 1 | 0 | ConductCognition |
| Digit Span Test | 1 | 0 | ConductCognition |
| Go/No-Go Task | 1 | 0 | ConductCognition |
| Letter-Number Sequencing Task | 1 | 0 | ConductCognition |
| Paired Associate Learning | 1 | 1 | ConductCognition |
1 to 10 of 17
See all 17 tests in its trialsData dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL741
GET https://conductscience.org/api/drugs/v1/CHEMBL741/diseases?page=2